AROA BIOSURGERY LIMITED (ARX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ARX

ARX - AROA BIOSURGERY LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 6.8
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.66

05 Dec
2025

-0.010

OPEN

$0.67

-1.49%

HIGH

$0.67

97,790

LOW

$0.66

TARGET
$0.82 24.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ARX: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 0.5 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 132.7 xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-1.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx77.1 M
Book Value Per Share xxxxxxxxxxxxxxx24.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-2.3 M
Net Profit Margin xxxxxxxxxxxxxxx-4.50 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-4.04 %
Return on Invested Capital xxxxxxxxxxxxxxx-3.81 %
Return on Assets xxxxxxxxxxxxxxx-3.46 %
Return on Equity xxxxxxxxxxxxxxx-4.04 %
Return on Total Capital xxxxxxxxxxxxxxx-3.96 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-4.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx5 M
Total Debt xxxxxxxxxxxxxxx6 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx20 M
Price To Book Value xxxxxxxxxxxxxxx1.73

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx3.4 M
Capex % of Sales xxxxxxxxxxxxxxx4.37 %
Cost of Goods Sold xxxxxxxxxxxxxxx11 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx70 M
Research & Development xxxxxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

26/11/2025

1

Upgrade to Buy from Accumulate

$0.79

19.70%

Aroa Biosurgery delivered a first half result that was below forecasts amid a lower contribution from Tela Bio and Enform.

Morgans notes FY26 guidance has been reiterated although revises down estimates to slightly above the midpoint of the range (EBITDA of NZ$5-8m) following the downgrade at Tela Bio.

The broker highlights the current share price weakness and upgrades to Buy from Accumulate, also noting that compared with domestic peers the business is trading at attractive levels. Target edges down to $0.79 from $0.80.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.54 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.99 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

25/11/2025

1

Buy

$0.90

36.36%

Aroa Biosurgery has delivered a first half result that was in line with expectations. Canaccord Genuity highlights the maintenance of guidance despite a softer outlook from the Tela Bio result.

The investor briefing focused on the quality and usability of the Ovitex product suite and the broker believes the company is taking the right actions to set the Tela Bio business up for longer-term success.

No changes were made to forecasts and Canaccord Genuity assesses the stock is "cheap", maintaining a Buy rating. Target unchanged at 90c.
Access Extra Coverage Research History >

ARX STOCK CHART

FNArena News on ARX

1
Australian Broker Call *Extra* Edition – Dec 01, 2025

Dec 01 2025 - Daily Market Reports
2
Weekly Ratings, Targets, Forecast Changes – 28-11-25

Dec 01 2025 - Weekly Reports
3
FNArena Corporate Results Monitor – 28-11-2025

Nov 28 2025 - Australia
4
Australian Broker Call *Extra* Edition – Oct 28, 2025

Oct 28 2025 - Daily Market Reports
5
Weekly Ratings, Targets, Forecast Changes – 17-10-25

Oct 20 2025 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
2
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
3
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
4
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
5
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
6
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
7
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
8
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
9
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
10
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia